A sensitive UPLC-MS/MS method was developed and validated for simultaneous estimation of aliskiren hemifumarate (ALS), amlodipine besylate (AML) and hydrochlorothiazide (HCZ) in spiked human plasma using valsartan as an internal standard (IS). Liquid-liquid extraction was used for purification and pre-concentration of analytes. The mobile phase consisted of 0.1% formic acid in ammonium acetate buffer (0.02 M, pH 3.5) and methanol (25:75, v/v), flowing through XBridge BEH (50 3 2.1 mm ID, 5 mm) C18 column, at a flow rate of 0.6 mL min 21 . Multiple reaction monitoring (MRM) transitions were measured using an electrospray source in the positive ion mode for ALS and AML, whereas HCZ and IS were measured in negative ion mode. Validation of the method was performed as per US-FDA guidelines with linearity in the range of 2.0 -400.0, 0.3 -25.0 and 5.0 -400.0 ng mL 21 for ALS, AML and HCZ, respectively. In human plasma, ALS, AML and HCZ were stable for at least 1 month at 270 + + + + + 58 8 8 8 8C and for at least 6 h at ambient temperature. After extraction from plasma, the reconstituted samples of ALS, AML and HCZ were stable in the autosampler at ambient temperature for 6 h. The LC-MS/MS method is suitable for bioequivalence and pharmacokinetic studies of this combination.
Introduction
Aliskiren hemifumarate (ALS) is chemically known as 2(S),4(S), 5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate ( Figure 1A ). Aliskiren is the first orally taken direct renin inhibitor simulating endogenous peptides approved for clinical use. By achieving more complete reninangiotensin system inhibition, direct renin inhibitors may afford greater protection from hypertensive complications (1) . Present evidence indicates that aliskiren reduces baseline systolic and diastolic blood pressure and that it is as effective as other firstline antihypertensive agents. Extra advantages can be reached when it is used in combination therapy (1) . Amlodipine besylate (AML; 3-ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulfonate) ( Figure 1B ) is a dihydropyridine long-acting calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle (2) . Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscles causing a reduction in peripheral vascular resistance and reduction in blood pressure (3) . Hydrochlorothiazide (HCZ) is a potent diuretic and antihypertensive agent, which inhibits active chloride reabsorption and thus increases the excretion of sodium chloride and water (4) . It is chemically known as 6-chloro-1,1-dichloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphanomide-1,1-dioxide ( Figure 1C ). Triple combination therapy of ALS, AML and HCZ proved to be effective and well tolerated in treating hypertensive high-risk patients (5) . Literature survey revealed some LC (6 -12), CE (13), UV-spectrophotometric (14, 15) and spectroflourimetric (16) (17) (18) methods for estimation of ALS alone or in combination with other antihypertensive agents. Methods such as LC (12, 19 -21) , LC-MS/MS (2), CE (22) , UV-spectrophotometry (23 -25) and spectrofluorimetry (26, 27) were reported for estimation of AML only or in combination with other agents. Moreover, methods such as LC (28 -33) , LC-MS/MS (34 -37), UPLC (38) and UV-spectrophotometry (39) were reported for the estimation of HCZ alone or in combination with other antihypertensive agents. Regarding the simultaneous determination of ALS, HCZ and AML triple mixture, there are four reported LC methods (11, 40 -42) with UV detection and one reported CE method (43) for their determination in pharmaceutical dosage forms. LC methods with UV detection are not sensitive enough to measure ALS, AML or HCZ in human plasma, while the use of GC-MS/ MS requires derivatization steps prior to analysis. Among the reported LC-MS/MS methods, there was no developed one for simultaneous determination of ALS, AML and HCZ in biological fluids. Thus, the aim of the present work was to develop a highly selective and sensitive LC-MS/MS method with good precision and accuracy, besides a simple sample treatment procedure, for simultaneous estimation of ALS, AML and HCZ in human plasma, using valsartan as the internal standard (IS). A detailed validation of the proposed method was performed in accordance with US-FDA guidelines (44) to yield reliable results. Moreover, the developed method can be successfully applied for further research to assess for instance the pharmacokinetics of ALS, AML and HCZ in combination.
Experimental

Materials and reagents
Working standards of ALS (certified to contain 99.51%) was supplied by Novartis Pharmaceuticals Co., NJ, USA; and AML (certified to contain 99.75%) was kindly supplied by Global Nabi Co., Giza, Egypt. HCZ (certified to contain 99.93%) was supplied by AstraZeneca, Cairo, Egypt. Pharmaceutical grade valsartan USP (certified to contain 99.40%) was supplied by Zydus Pharmaceuticals, NJ, USA. Methanol HPLC grade, methyl tert-butyl ether and ammonium acetate were obtained from Sigma-Aldrich, USA. Formic acid was obtained from El-Nasr Pharmaceutical Chemicals Co., Egypt. Human plasma was obtained from VACSERA Blood Bank, Egypt. Deionized and purified water produced in-house from Millipore's Milli-Q System (USA) was used throughout the analysis.
Instruments and conditions
Quantitation was performed via MS/MS detection using Waters ACQUITY triple quadrupole LC-MS/MS mass spectrometer (Waters Corp., Milford, MA, USA). A Waters series UPLC system (Waters Corp.) equipped with degasser, electrospray interface (ESI) and a solvent delivery unit along with an autosampler was used to inject 10 mL aliquots of the processed samples. The chromatographic separation was carried out on an XBridge BEH (50 Â 2.1 mm ID, 5 mm) C18 column obtained from Waters. Soniclean120T ultrasonic processor (Australia), Eppendorf Vacufuge 5301 Vacuum Centrifuge Concentrator (Germany) and Vortex-2 G-560 Lab Shaker Mixer (USA) were used as well.
Chromatographic elution was performed with a mobile phase consisted of 0.1% formic acid in 20 mM ammonium acetate and methanol, pH 3.5 (25:75, v/v), pumped through the column at a flow rate of 0.6 mL min 21 . The column temperature was maintained at 308C. Under these conditions, the retention times for HCZ, AML, ALS and IS were at 1.20, 2.91, 3.21 and 2.04 min, respectively ( Figure 2 ). The injection volume was 10 mL. The LC-MS/MS system allowed using the positive ion mode for monitoring ALS and AML as well as the negative ion mode for monitoring HCZ and IS simultaneously in each run. Multiple reaction monitoring (MRM) is a highly sensitive method of targeted mass spectrometry that can be used to selectively detect and quantify specific molecules in a complex mixture based on the screening of specified precursor molecule-to-fragment ion transitions (45) . for the IS, where CV is the cone voltage and CE is the value of collision energy for MRM acquisition, with a 20-ms dwell time of all analytes. The capillary voltage was set at þ4000 V for both of ALS and AML, while it was set at 24000 V for HCZ and IS. The cone gas flow was set at 40 L h 21 at 4 psi, and temperature at 3508C with a nozzle voltage of 2900 V. Nitrogen (99.99% purity) was used in the ion source and the collision cell. Quantitation of the analytes in spiked human plasma was based on the peak area ratio of the cited drugs to the IS. Data acquisition and processing were performed using Empower2 software (Waters Corp.).
Standard stock solutions preparation
Standard stock solutions of 200 mg mL 21 of ALS and HCZ as well as 100 mg mL 21 of AML and IS were prepared separately in methanol. Appropriate further dilutions were prepared in the same solvent. All solutions were stored under refrigeration (2 -8 8 C) when not in use.
Procedure
Calibration and quality control samples preparation Seven non-zero calibration standard solutions ranging from 20 to 4000 ng mL 21 for ALS, 3 to 250 ng mL 21 for AML and 50 to 4000 ng mL 21 of HCZ were prepared in 10 mL volumetric flasks, and 100 mL of IS stock solution was added to each flask and completed to the mark with methanol. Then, 50 mL of each working solution was added to 450 mL of drug-free human plasma containing EDTA as anticoagulant. The quality control (QC) samples were prepared in the same manner similar to the calibration standards at three concentration levels; low, medium and high (60, 1600 and 3200 ng mL 21 ), (9, 100 and 200 ng mL 21 ), (150, 1600 and 3200 ng mL 21 ) for ALS, AML and HCZ, respectively.
All samples were vortexed to ensure complete mixing. During each run, five replicates of the QC samples were used along with the calibration standards to verify the repeatability and integrity of the method.
Sample preparation
To 500 mL of each spiked calibration plasma standard or QC sample, 4 mL of methyl tert-butyl ether was added. It was then vortexed for 30 s and centrifuged at 4000 rpm, at 48C for 5 min. Furthermore, 1350 mL of the supernatant was collected and evaporated using an Eppendorf concentrator. The residue was reconstituted in 150 mL of the mobile phase and transferred to a glass vial for LC-MS/MS analysis.
Discussion and method development
To the best of our knowledge, there is no reported method for simultaneous determination of ALS, AML and HCZ in human plasma using LC-MS/MS, so the aim of the present work was to simultaneously determine ALS, AML and HCZ using UPLC system interfaced with tandem mass spectroscopy to attain higher sensitivity and selectivity for detection and quantitation of the cited drugs in human plasma with a rapid and affordable extraction procedure. Moreover, the proposed method should be suitable for human clinical pharmacology, bioavailability and bioequivalence studies requiring simultaneous pharmacokinetic evaluation of ALS, AML and HCZ either separately or in combination in human plasma. Peak plasma concentrations for ALS reach 186 + 91 ng mL 21 following oral administration of a single oral dose (300 mg) of ALS (46) . In addition, peak plasma concentrations for AML and HCZ reach 6.7 + 1.2 and 131 + 4 ng mL 21 following oral administration of single oral doses (10 and 25 mg) of AML (47) and HCZ (48), respectively. Based on the C max value of each drug, suitable linearity ranges of 2.0 -400.0, 0.3 -25.0 and 5.0 -400.0 ng mL 21 for ALS, AML and HCZ, respectively, were selected. For sample preparation, extraction methods including direct precipitation and liquid -liquid extraction were studied. Liquid -liquid extraction using 4 mL methyl tert-butyl ether as the extraction solvent has the advantage of better deproteinization of the plasma samples, lower cost and good recovery results for the cited drugs (Table I ). The use of C18 column was suitable for optimum separation of ALS, AML and HCZ. During the optimization cycle, various mobile phase compositions of ammonium acetate buffer, 0.1% formic acid in water, 0.1% formic acid in 20 mM ammonium acetate buffer, methanol and acetonitrile, in different proportions were tried in an isocratic mode. It was found that methanol allowed good elution of the analytes with better responses. The use of 0.1% formic acid in 20 mM ammonium acetate buffer was to obtain higher detection response through assisting the ionization of the cited drug molecules, especially AML. Thus, the optimized conditions allowed the proposed method to be selective, sensitive, rapid and suitable for human clinical pharmacology, bioavailability and bioequivalence studies requiring pharmacokinetic simultaneous evaluation of ALS, AML and HCZ combination in human plasma.
Results and Bio-analytical method validation
Calibration, linearity and limit of quantitation Blank samples (matrix samples processed without IS) and zero samples (matrix samples processed with IS) were analyzed. To establish the linearity, seven non-zero samples covering the expected range of each drug were prepared and added to drug-free human plasma and then analyzed. Calibration curves were constructed by plotting the peak area ratio of the cited drugs to the IS versus the corresponding concentration. Satisfactory linearity was obtained in the concentration range of 2.0 -400.0, 0.3 -25.0 and 5.0 -400.0 ng mL 21 for ALS, AML and HCZ, respectively. The lowest standard on the calibration curve was to be accepted as the lower limit of quantitation (LLOQ) if the analytes response in the standard was at least five times more than that of drug-free (blank) plasma (44) . In addition, the analyte peak in the LLOQ sample was identifiable, discrete and reproducible with satisfactory precision and accuracy (Table II) . A correlation coefficient of more than 0.998 for each of the analytes was obtained (Table III) . The regression equation for each of the cited drugs was also computed (Table III) .
Specificity
Six randomly selected drug-free human plasma samples were processed by the similar liquid -liquid extraction procedure and analyzed. No endogenous plasma components showed interference at retention time of any analyte or of the IS.
Recovery (extraction efficiency) from human plasma matrix Recovery of ALS, AML and HCZ were evaluated by comparing the mean peak responses of five extracted QC samples of low, medium and high concentrations to mean peak responses of five plain standards of equivalent concentration. Similarly, the recovery of IS was also evaluated at the concentration of 100 ng mL 21 . The recovery of the analytes was consistent, precise and reproducible. The mean recovery results for the cited drugs in human plasma are listed in Table I . The recovery for the IS from plasma was found to be 88.54 + 1.91 (mean recovery % + SD).
Accuracy and precision (inter-and intraday)
The satisfactory recovery percentage results obtained from the assay of ALS, AML and HCZ indicate the accuracy of the proposed method (Table IV) . Repeatability (intraday) and intermediate precision (interday) were assessed using three concentrations and three replicates of each concentration. The intermediate precision was performed over three different days. The acceptable values for the coefficient of variation indicate good precision of the proposed method (Table IV) .
Stability
Three aliquots each of the low and high unprocessed QC samples of ALS, AML and HCZ were stable at 270 + 58C for 36 days (longterm stability) in human plasma (Table V) . Furthermore, three 
where C is the concentration in ng/mL and Y is the peak area ratio. aliquots each of the low and high unprocessed QC samples of ALS, AML and HCZ were found to be stable over 6.0 h in human plasma at room temperature (23 -308C) (short-term stability). After 6.0 h the samples were processed, analyzed and compared with nominal concentrations (Table V) . Autosampler stability was determined by analyzing three aliquots each of low and high QC samples of ALS, AML and HCZ that were stable for 6.0 h after sample processing (Table V) . Three aliquots each of low and high unprocessed QC samples were stored at 270 + 58C and subjected to three freeze and thaw cycles. After the completion of third cycle, the samples were processed, analysed and the results were compared with nominal values (Table V) . Working solutions of 320 ng mL 21 of ALS and HCZ as well as 20 and 100 ng mL 21 of AML and IS, respectively, were found to be stable for 6 days at 2-88C and at room temperature (23-308C) for 6 h (Table VI) .
Conclusion
The proposed bio-analytical method described in this investigation was specific, sensitive, accurate and precise enough to be successfully applied to human clinical pharmacology, bioavailability and bioequivalence studies requiring pharmacokinetic evaluation. The method employed sample preparation by liquid -liquid extraction with adequate recovery results, followed by isocratic UPLC coupled with tandem mass spectrometric detection. The LC-MS/MS method was rapid enough and capable of simultaneous estimation of ALS, AML and HCZ in human plasma with satisfactory sensitivity and precision. 
